Oxapex®

PRODUCT FACTSHEET

Haemoglobin based therapeutic for dogs with anaemia

ACTIVE INGREDIENT

Each mL contains: 65 mg hemoglobin betafumaril (bovine)
Osmolality: 250-350 mOsm/kg
pH: 7.2-7.6
Dark purple solution for infusion

INDICATION

Oxapex is intended to increase systemic plasma haemoglobin in dogs with acute anaemia.

DOSAGE

Oxapex is intended for single dose and single time administration only by intravenous infusion.
The recommended dose is 5-30 mL/kg of body weight administered intravenously at a rate of up to 10 mL/kg/hr. The dose selection will depend on patient condition.

METHOD OF ADMINISTRATION

Oxapex should be administered using aseptic technique via a standard intravenous infusion set with a filter and catheter. Use of Oxapex does not require typing or cross-matching of the recipient's blood.

ADVICE ON CORRECT ADMINISTRATION

The actual dose will be based upon the required increase of plasma haemoglobin levels as deemed necessary by the veterinarian. (See **Table 1**).

Table 1: Pharmacokinetics of Oxapex

Dose (mL/kg)	Immediate post infusion plasma haemoglobin concentration (g/dL)	Terminal half life(hr)
5	0.64	23
30	2.38	23

SPECIAL STORAGE PRECAUTIONS

Store below 25°C. Do not freeze.
Store in a dry place and protect from light.
Do not use after the expiry date stated on the label.
Use immediately after first opening the packaging.

CONTRAINDICATIONS

Do not use in dogs with identified kidney disease.
Do not use in dogs predisposed to circulatory overload.
Do not use in dogs with advanced cardiac disease (i.e. congestive heart failure) or otherwise severely impaired cardiac function.

ADVERSE REACTIONS

Reddish brown discoloration of skin, sclera, plasma, mucous membranes, urine and faeces.
Mild and transient GI effects e.g. vomiting, diarrhea.
Occasional sneezing.
Reactions at the site of infusion e.g. redness, swelling, may occur.

SPECIAL WARNINGS

Do not administer with other fluids or medicinal products concurrently via the same infusion set.
Do not add medications or other solutions to the infusion bag.
Do not combine the contents of more than one infusion bag.

- **Use during pregnancy, lactation or lay**
  The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

- **Overdose (symptoms, emergency procedures, antidotes)**
  Overdose or an excessive rate of administration (i.e. >10 mL/kg/hr) could result in immediate cardiopulmonary effects. Discontinue infusion immediately until signs abate. Treatment of circulatory overload may be necessary.

- **Special warnings for use in animals**
  Minor, reversible renal changes may result following administration of the product. In the event of such changes occurring renal function should be closely monitored until fully resolved.

- **Special precautions for use**
  Do not use in dogs previously treated with this product or other bovine haemoglobin based oxygen carriers to avoid a potential sensitivity type reaction upon repeat exposure.
  In patient with pre-existing haemolysis, routine analysis will not be able to distinguish Oxapex from native haemoglobin in plasma.
  Note that transient discolouration (sclera, urine, faeces, mucous membrane, skin) may occur and this may interfere with laboratory tests.

- **Special precautions for the disposal of unused product or waste materials**
  Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Reference: Oxapex package insert, 2020

Oxapex is a Restricted Veterinary Medicine. Available only under veterinary authorisation.
Registered under the ACVM Act 1997 No. A010809.

Registered in New Zealand by
New Alpha Innovation New Zealand Limited
66 Riverlea Road, Hillcrest, Hamilton 3216, New Zealand
Hotline: 0800 463 9269 Email: nz.info@newalphainnovation.com

NZ.OXA.11.20 (10.2022)

New α Innovation